Právní předpis byl sestaven k datu 12.04.2025.
Zobrazené znění právního předpisu je účinné od 01.01.2025.
419
NAŘÍZENÍ XXXXX
xx xxx 11. xxxxxxxx 2024,
xxxxxx xx xxxx xxxxxxxx xxxxx x. 463/2013 Xx., o seznamech xxxxxxxxxx xxxxx, xx xxxxx pozdějších xxxxxxxx
&xxxx;
Xxxxx xxxxxxxx xxxxx §44c xxxx. 1 a 2 zákona č. 167/1998 Xx., o xxxxxxxxxx látkách x x změně xxxxxxxxx xxxxxxx xxxxxx, ve xxxxx xxxxxx x. 273/2013 Sb. x xxxxxx č. 366/2021 Xx.:
Xx. X
Xxxxxxxx xxxxx x. 463/2013 Xx., x seznamech xxxxxxxxxx xxxxx, xx xxxxx xxxxxxxx xxxxx x. 243/2015 Sb., nařízení xxxxx x. 46/2017 Xx., nařízení xxxxx x. 30/2018 Sb., xxxxxxxx xxxxx x. 242/2018 Sb., xxxxxxxx xxxxx č. 184/2021 Xx., xxxxxxxx xxxxx x. 159/2022 Xx., xxxxxxxx vlády č. 228/2023 Sb., xxxxxxxx xxxxx x. 52/2024 Xx. x xxxxxxxx xxxxx č. 176/2024 Xx., xx xxxx xxxxx:
1. V xxxxxxx xxxxxxx x. 1 xx xxx xxxxx, xx kterém xx xx xxxxxxx x xxxxxx „Xxxxxxxxxxx xxxxxxxxxx xxxxx (XXX) x xxxxxx xxxxxx“ uvedeno xxxxx „Thebakon“, xxxxxx xxxx xxxxx, xx xxxxxx je xx xxxxxxx x názvem „Xxxxxxxxxxx xxxxxxxxxx xxxxx (XXX) v xxxxxx xxxxxx“ uvedeno xxxxx „Xxxxxxxxxxxx“, xx xxxxxxx x xxxxxx „Xxxxxxxx xxxxx xxxxx IUPAC“ xx xxxxxxx slovo „xxxxxx 4-(N-(2-methoxyacetyl)anilin)-1-(2-thiofen-2-ylethyl)piperidin-4-karboxylát“ x xx xxxxxxx x xxxxxx „Poznámka“ xxxx xxxxxxx xxxxx „A-3080, Xxxxxxx“.
2. Xxxxxxx x. 3 zní:
„Příloha x. 3
Xxxxxx x. 3 xxxxxxxx xxxxx
|
Xxxxxxxxxxx xxxxxxxxxx xxxxx (INN) v českém xxxxxx / xxxxxx xxxxx |
Xxxxx xxxxxxxxxxx nechráněný xxxxx nebo xxxxx xxxxxx xxxxx |
Xxxxxxxx název xxxxx XXXXX |
Xxxxxxxx |
|
Xxxxxxxxxxxxxxxxxxxx |
xxxxxxxxxxxxxxxxxxxx |
X-xxxxx-X-(1-xxxxxx-xxxxxxxxx-4-xx)-xxxxxxxx |
XXX 73750 |
|
Xxxxxxxxxxxxxx |
X-xxxxx-X-[1-(2-xxxxxxxxxx)-4-xxxxxxxxxxx]xxxxxxxx |
||
|
Xxxxxxxxxxxxxxxx |
Xxxxxxxxxxxxx |
X-xxxxx-X-[1-(2-xxxxxxxxxx)xxxxxxxxx-4-xx]xxxx-2-xxxxxx |
|
|
XX-7921 |
3,4-xxxxxxx-X-{[1-(xxxxxxxxxxxxx)xxxxxxxxxx]xxxxxx}xxxxxxxx |
||
|
XX-237 |
xxxxxxxxxx; 1-X-xxxxxxx-4- xxxxxxxxxxxxxxxxxx; |
1-[4-(3-xxxxxxxxx-2-xx-1-xx)xxxxxxxxx-1-xx]xxxxx-1-xx |
|
|
XX-238 |
1-[2,6-xxxxxxxx-4-(3-xxxxxxxxx-2-xxxx)xxxxxxxxx-1-xx]xxxxxx-1-xx |
||
|
Xxxxxxxxxxxxxxxxxxx |
XXX-X; xxxxxxxxxxxx-X |
X-xxxxx-X-[1-(2-xxxxxxxxxx)xxxxxxxxx-4-xx-1-2X-1,3-xxxxxxxxxxx-5-xxxxxxxxxx |
|
|
Xxxxxxxxxxxxxxxxxxxxx |
X-xxxxx-X-(1-xxxxxx-xxxxxxxxx-4-xx)xxxxxxxx |
||
|
Xxxxxxxxxxxxxxx |
xxxxxxxxxxxxx |
X-xxxxx-X-[1-(2-xxxxxxxxxx)xxxxxxxxx-4-xx]xxxxxxxx |
|
|
Xxxxxxxxxxxxxx |
Xxxxxx-X; X4129 |
X-xxxxx-X-[1 -(xxxxxxxxxxx)xxxxxxxxx-4-xx]xxxxxxxxxx |
|
|
Xxxxxxxxxxxxxxxxxxxxx |
Xxxxxx XxX |
X-(1-xxxxxxxxxxxxxxx-4-xx)-X-xxxxxxxxxx-2-xxxxxxxxxx |
|
|
Xxxxxxxxxx |
X 4793x; X 47931X |
4-xxxx-X-(2-(xxxxxxxxxxxxx) xxxxxxxxxx) xxxxxxxx |
|
|
Xxxxxxx |
Xxxxxxxxx |
3-{1-[1-(4-xxxxxxxxx)xxxxx]xxxxxxxxx-4-xx}-1X-xxxxxxxxxxxx-2-xx |
|
|
Xxxxxxxxxxx |
2-[(4-xxxxxxxxxxx)xxxxxx]-X,X-xxxxxxx-5-xxxxx-xX-xxxxxxxxxxxx-1-xxxxxxxxx |
||
|
4-Xxxxxxxxxxxxxxxxxxxxx |
4-Xx-xXX |
X-(4-xxxxxxxxxx)-2-xxxxxx-X-[1-(2-xxxxxxxxxx)-4-xxxxxxxxxxx]xxxxxxxxxx |
|
|
Xxxxxxxxxxxxxxxxxxx |
xxxxxxxxxxx-X; CP-F |
N-fenyl-N-[1-(2-fenylethyl)piperidin-4-yl]cyklopentankarboxamid |
|
|
Cyklopropylfentanyl |
N-fenyl-N-[1-(2-fenylethyl)piperidin-4-yl]cyklopropankarboxamid |
||
|
Desmethylmoramid |
R530 |
4-(4-morfolinyl)-2,2-difenyl-1-(1-pyrrolidinyl)-1-butanon |
|
|
Desomorfin |
4,5α-epoxy-17-methylmorfinan-3-ol |
||
|
Despropionyl-2-fluor xxxxxxxx |
X-(2-xxxxxxxxxx)-1-(2-xxxxxxxxxx)xxxxxxxxx-4-xxxx |
||
|
Xxxxxxxxxxxx-4-xxxxx xxxxxxxx |
X-(4-xxxxxxxxxx)-1-(2-xxxxxxxxxx)xxxxxxxxx-4-xxxx |
||
|
Xxxxxxxx |
4,4-xxxxxxx-6-(xxxxxxxxxx-1-xx)xxxxxx-3-xx |
||
|
Xxxxxx |
xxxxxxxxxxxxxx |
2-[2-[(4-xxxxxxxxxxx)xxxxxx]xxxxxxxxxxxx-1-xx]-X,X-xxxxxxxxxxxxxxxx |
|
|
Xxxxxxxxxxxxxxxxx |
2-{2-[(2,3-xxxxxxx-1-xxxxxxxxxx-5-xx)xxxxxx]-5-xxxxx-1X-xxxxxxxxxxxx-1-xx}-X,X- xxxxxxxxxxxx-1-xxxx |
||
|
Xxxxxxxxxx |
5-xxxxxx xxxxxxxxxxxxx; 5-xxxxxx desnitroetonitazen |
2-[(4-ethoxyfenyl)methyl]-N,N-diethyl-5-methyl-1H-benzimidazol-1-ethanamin |
|
|
Etonitazepipne |
N-piperidinyletonitazen |
2-(4-ethoxybenzyl)-5-nitro-1-(2-(piperidin-1-yl)ethyl)-1N-benzo[d]imidazol |
|
|
Etonitazepin |
2-[(4-ethoxyfenyl)methyl]-5-nitro-1-(2-pyrrolidin-1-ylethyl)-1H-benzoimidazol |
||
|
Etorfin |
(5R,6R,7R,14R)-4,5-epoxy-7-[(2R)-2-hydroxypentan-2-yl]-6-methoxy-17-methyl-6,14-ethenomorfinan-3-ol |
||
|
Fentanyl xxxxxxxxx xxxxxx |
xxxxxxxxxxxxx |
X-xxxxx-X-[1-(2-xxxxxxxxxx)-4-xxxxxxxxxxx]-xxxxxxxxx |
|
|
3 -Xxxxxxxxxxxxxxxxxxxxx |
β'-xxxxxxxxxxxxx |
X-xxxxx-X-[1-(2-xxxxxxxxxx)xxxxxxxxx-4-x]-3-xxxxxxxxxxxxxxx |
xxxxxxxxxxxxxxxxxxxxxx |
|
Xxxxxxxxxx |
X,X-xxxxxxx-2-{2-[(4-xxxxxxxxxx)xxxxxx]-5-xxxxx-1X-xxxxxxxxxxxx-1-xx}xxxxxxxxx |
||
|
2’-Xxxxx-2-xxxxx-3-xxxxxxxxxxxxxx |
X-(1-(2-xxxxxxxxxxxxx)-3-xxxxxxxxxxxxxxx-4-xx)-X-(2-xxxxxxxxxx)xxxxxxxxxxx |
||
|
4-Xxxxx-xxxxxxxxxxxxx |
4X-XX |
X-(4-xxxxxxxxxx)-X-[(1-(2-xxxxxxxxxx)-4-xxxxxxxxxxx)]xxxxxxxxx |
|
|
4-Xxxxx-xxxxxxxxxxxxxxxxxxxxxxxxx |
xxxx-xxxxxxxxxxxxxxxxxxxxxx- xxxxxxxx |
X-(4-xxxxxxxxxx)-X-(1-xxxxxxxxxxxxxxx-4-xx)-xxxxxxxxxxxxxxxxxxxxx |
|
|
2-Xxxxxxxxxxxxx |
Xxxxxxxxxxxxxxxxx |
X-(2-xxxxxxxxxx)-X-[1-(2-xxxxxxxxxx)-4-xxxxxxxxxxx]xxxxxxxxxx |
2-XX, x-XX |
|
3-Xxxxxxxxxxxxx |
Xxxxxxxxxxxxxxxxx |
X-(3-xxxxxxxxxx)-X-[1-(2-xxxxxxxxxx)-4-xxxxxxxxxxx]xxxxxxxxxx |
3-XX, m-FF |
|
4-Fluorfuranylfentanyl |
para-fluorfuranylfentanyl; 4X-xxxxxxxxxxxxxxx |
X-(4-xxxxxxxxxx)-X-(1-xxxxxxxxxxxxxxxxx-4-xx)xxxxx-2-xxxxxxxxxx |
|
|
4-Xxxxxxxxxxxxxxxxxxxxx |
4X-1XX |
X-(4-xxxxxxxxxx)-2-xxxxxx-X-[1-(2-xxxxxxxxxx)-4-xxxxxxxxxxx]xxxxxxxxxx |
|
|
3-XxxxxxxxxxxxxxxxxXxxxxxxxx |
xxxxx-xxxxxxxxxxxxxxxxxx- xxxxxxxx |
X-(3-xxxxxxxxxx)-2-xxxxxxx-X-[1-(2-xxxxxxxxxx)xxxxxxxxx-4-xx]xxxxxxxx |
|
|
2X-xxxxxxx |
2-[xx(xxxxx-2-xx)xxxxx]-1-[1-(2-xxxxxxxxxxx)-1X-xxxxxx-2-xx]xxxxx-1-xx |
||
|
Xxxxxxx XX-17 |
X-[2-(xxxxxxxxxxxxx)xxxxxxxxxx]-X-xxxxx-xxxxx-2-xxxxxxxxxx |
||
|
Xxxxxxxxxxxxxxx |
XX-X; 2-xxxxxxxxxxxxxxxx |
X-xxxxx-X-[1-(2-xxxxxxxxxx)xxxxxxxxx-4-xx]-xxxxx-2-xxxxxxxxxx |
|
|
(xxx)Xxxxxxx-X-xxxxxxxx X-xxxxxx xxxxxx |
X-(1-xxxxxxxxxxxxxxx-4-xx)-X-(4-xxxxxxxxxx)xxxxxxxxx |
||
|
Xxxxxx |
(5X,6X)-4,5-xxxxx-17-xxxxxxxxxxxx-7-xx-3,6-xxxx-xxxxxxxx |
||
|
4-xxxxxxxxxxxxxxxxxxxx |
4-XX-XX; p-hydroxybutyryl xxxxxxxx |
X-(4-xxxxxxxxxxxx)-X-[1-(2-xxxxxxxxxx)xxxxxxxxx-4-xx]-xxxxxxxxx |
|
|
Xxxxxxxxxxxxxxxx |
2-xxxxxx-X-xxxxx-X-[1-(2-xxxxxxxxxx)xxxxxxxxx-4-xx]xxxxxxxxxx |
||
|
Xxxxxxxxx-X-47700 |
3,4-xxxxxxxX-[2-(xxxxxxxxxxxxx)xxxxxxxxxx]-X-(xxxxxx-2-xx)xxxxxxxx |
||
|
Xxxxxxxxxxxx |
X,X-xxxxxxx-2-[[4-(1-xxxxxxxxxxxx)xxxxx]xxxxxx]-5-xxxxx-1X-xxxxxxxxxxxx-1-xxxxx xxxx |
||
|
Xxxxxxxx-xxxxxxxx |
(4-xxxxxxxxx)-(1-(xxxxxxxxxxxxx)-4-xxxxxxx-4-xxxxxxxxxxxxxxxxxx)xxxxxxxx |
||
|
Xxxxxxxxxxx |
1-[4-(3-xxxxxxx fenyl)-1 -xxxxxxxxxxxxxxx-4-xx]xxxxxx-1-xx |
||
|
Xxxxxx |
X výjimkou xxxxxx xxx xxxxxxx xxxxxxx xxxxxxx x xxxxxxx x.&xxxx;1 |
||
|
Xxxxxxxxxxxxxxxx |
(2X)-X-xxxxx-X-[1-(2-xxxxxxxxxx)xxxxxxxxx-4-xx]-2-xxxxxxxxx |
||
|
Xxxxxxxxxxxxxxxxxxxxx |
Xxxxxxx-XxX |
2-xxxxxxx-X-xxxxx-X-[1-(2-xxxxxxxxxx)xxxxxxxxx-4-xx]xxxxxxxx |
|
|
4-Xxxxxxxxxxxxxxxxxxxx |
4-XxX-XX |
X-(4-xxxxxxxxxxxx)-X-[1-(2-xxxxxxxxxx)xxxxxxxxx-4-xx]xxxxxxxxx |
|
|
2-Xxxxxxxxxxxxxxxxxxxx |
x-xxxxxxxxxxxxxxxxxxxx |
X-(2-xxxxxxxxxxx)-X-[1-(2-xxxxxxxxxx)-xxxxxxxxx-4-xx]-xxxxxxxx |
|
|
2-Xxxxxx-XX-237 |
2-xxxxxx-xxxxxxxxxx |
1-[2-xxxxxx-4-(3-xxxxxxxxx-2-xx-1-xx)xxxxxxxxx-1-xx]xxxxx-1-xx |
|
|
3,4-Xxxxxxxxxxxxx-X-47700 |
3,4-XXX-X-47700; 3,4-XXX-47700; MDU-47; MDU-47700 |
N-(2-(dimethylamino)cyklohexyl)-N-methylbenzo[d][1,3]dioxol-5-karboxamid |
|
|
α-Methylfentanyl butanamid xxxxxx |
XX; X-X |
2-xxxxxx-X-xxxxx-X-[1-(1-xxxxxxxxxxx-2-xx)xxxxxxxxx-4-xx]xxxxxxxxxx |
|
|
3 -XxxxxXxxxxxxxXxxxxxxxx |
β'-xxxxxXxxxxxxxXxxxxxxxx |
X-xxxxx-X-[1-(2-xxxxxxxxxx)-xxxxxxxxx-4-xx]-3-xxxxxxxxx-2-xxxxxx |
|
|
Xxxxxxxxxxxxxx |
X,X-xxxxxxx-2-[2-[(4-xxxxxxxxxxxx)xxxxxx]xxxxxxxxxxxx-1-xx]xxxxxxxxx |
||
|
Xxxxxxxxxxx |
X,X-xxxxxxx-2-[2-[(4-xxxxxxxxxxxx)xxxxxx]-5-xxxxxxxxxxxxxxxxx-1-xx]xxxxxxxxx |
||
|
Xxxxxxxxxxxxx |
2-(4-xxxxxxxxxxxxx)-5-xxxxx-1-(2-(xxxxxxxxxx-1-xx)xxxxx)-1X-xxxxx[x]xxxxxxxx |
||
|
XX-45 |
1-xxxxxxxxxx-4-(1,2-xxxxxxxxxxxx)xxxxxxxxx |
||
|
X-xxxxxxxxxxxxxxxxxx |
2-[2-[(4-xxxxxxxxxxx)xxxxxx]-5-xxxxx-xxxxxxxxxxxx-1-xx]-X-xxxxx-xxxxxxxxx |
||
|
X-xxxxxxxxxxxxxxxxxxxx |
X-xxxxx-2-[2-[(4-xxxxxxxxxxxxxxx)xxxxxx]-5-xxxxx-xxxxxxxxxxxx-1-xx]xxxxxxxxx |
||
|
X-xxxxxx X-47931X |
X-xxxxxxxxxxxxxxxx |
4-xxxx-X-(2-(xxxxxxxxxxxxx)xxxxxxxxxx)-X-xxxxxxxxxxxxxx |
|
|
Xxxxxxxxxx |
xxxxx 2-xxxxxxxxxxx-1-xxxxxxxxxxxxx-3-xx-1-xxxxxxxxxx |
||
|
X-XXXX; xxxxxxxxxxxxxxxxxxxxxxxx |
3-(4-xxxxxx-1-xxxxxxxxxxxxxxx-4-xx)xxxxx acetát |
||
|
OCfentanyl |
A-3217 |
N-(2-fluorfenyl)-2-methoxy-N-[1-(2-fenylethyl)piperidin-4-yl]acetamid |
|
|
Piperidylthiambuten |
piperidinohton, XXX, 127X49 |
1-(4,4-xx(xxxxxxx-2-xx)xxx-3-xx-2-xx)xxxxxxxxx |
|
|
Xxxxxxxxxxxx |
X,X-xxxxxxx-5-xxxxx-2-[(4-xxxxxxxxxxxx)xxxxxx]-1-X-xxxxxxxxxxxx-1-xxxxxxxxx |
||
|
Xxxxxxxxxxxxxx |
5-xxxxx-2-[(4-xxxxxxxxxxxxx)xxxxxx]-1-(2-xxxxxxxxxx-1-xxxxxxx)xxxxxxxxxxxxx |
||
|
Xxxxxxxxxx x&xxxx;xxxxxx |
|||
|
Xxxxxxxxxxxxxxxxxxxxxxx |
XXX-X |
X-(1-xxxxxxxxxxxxxxxxxxx-4-xx)-X-xxxxxxxxxxxxxxxxxxxx-2-xxxxxxxxxx |
|
|
Xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx |
XXXX-xxxxxxxx; XXXX-X |
X-xxxxx-X-[1-(2-xxxxxxxxxx)xxxxxxxxx-4-xx]-2,2,3,3-xxxxxxxxxxxxxxxxxxxxxx-1- karboxamid |
|
|
Thiofenfentanyl |
2-thiofuranyl xxxxxxxx |
X-(1-xxxxxxxxxxxxxxxxx-4-xx)-X-xxxxxxxxxxxx-2-xxxxxxxxxx |
|
|
4-(Xxxxxxxxxxxxxx) X-47700 |
X-(2-(xxxxxxxxxxxxx)xxxxxxxxxx)-X-xxxxxx-4-(xxxxxxxxxxxxxx)xxxxxxxx |
||
|
X-47700 |
3,4-xxxxxxx-X-[2-(xxxxxxxxxxxxx)xxxxxxxxxx]-X-xxxxxxxxxxxxxx |
||
|
X-48800 |
2-(2,4-xxxxxxxxxxxx)-X-(2-(xxxxxxxxxxxxx)xxxxxxxxxx)-X-xxxxxxxxxxxxxx |
||
|
X-49900 |
3,4-xxxxxxx-X-[2-(xxxxxxxxxxxx)xxxxxxxxxx]-X-xxxxxxxxxxxxxx |
||
|
X-50488 |
3,4-xxxxxxx-X-xxxxxx-X-[2-(1-xxxxxxxxxxxx)xxxxxxxxxx] xxxxxxxxxxxxxx |
||
|
X-51754 |
2-(3,4-xxxxxxxxxxxx)-X-[2-(xxxxxxxxxxxxx)xxxxxxxxxx]-X-xxxxxxxxxxxxxx |
||
|
XxxxxxXxxxxxxxx |
XXX, VF |
A-fenyl-N-[1-(2-fenylethyl)-4-piperidyl]pentanamid; xxxxxxxx xxxxxxxxxx xxxxxx |
Xxxxxx xxxx omamných xxxxx xxxxxxxxx x této xxxxxxx xx všech xxxxxxxxx, xxx xxxx xxxx xxxxx xxxxxxxxx.“.
3. X xxxxxxx xxxxxxx x. 6 xx xxx řádek, xx xxxxxx xx xx xxxxxxx x xxxxxx „Xxxxxxxxxxx xxxxxxxxxx název (XXX) x xxxxxx xxxxxx“ uvedeno xxxxx „Xxxxxxxxxxxxx“, xxxxxx nový xxxxx, xx xxxxxx xx xx xxxxxxx x xxxxxx „Xxxxxxxxxxx xxxxxxxxxx xxxxx (INN) x českém xxxxxx“ xxxxxxx xxxxx „Xxxxxxxxxxxxxxxx“, xx xxxxxxx x xxxxxx „Xxxxx mezinárodní xxxxxxxxxx xxxxx xxxx xxxxx xxxxxx xxxxx“ xx uveden xxxx „XXX“, xx sloupci x názvem „Xxxxxxxx xxxxx xxxxx XXXXX“ xx xxxxxxx xxxxx „xxxxxx-2-xx“ x ve xxxxxxx s xxxxxx „Xxxxxxxx“ je uvedeno xxxxx „gamma-butyrolactone“.
Čl. XX
Xxxxxxxxx xxxxxxx
Xxxx xxxxxxxx bylo xxxxxxxx x souladu se xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x Rady (XX) 2015/1535 xx dne 9. xxxx 2015 x xxxxxxx při xxxxxxxxxxx xxxxxxxxx x xxxxxxx xxxxxxxxxxx xxxxxxxx x xxxxxxxx xxx xxxxxx informační společnosti.
Xx. III
Účinnost
Toto nařízení xxxxxx xxxxxxxxx xxxx 1. xxxxx 2025, x xxxxxxxx xxxxxxxxxx čl. I xxxx 3, xxxxx xxxxxx účinnosti xxxx 1. xxxxx 2025.
&xxxx;
Xxxxxxxx xxxxx:
xxxx. PhDr. Xxxxx, Xx.X., XX.X., x. x.
&xxxx;
Xxxxxxxxxxxxx vlády x xxxxxxx zdravotnictví:
prof. XXXx. Xxxxx, XXx., XXX, XXXX, x. x.
Xxxxxxxxx
Xxxxxx předpis x. 419/2024 Sb. xxxxx xxxxxxxxx xxxx 1.1.2025, x xxxxxxxx ustanovení čl. I bodu 3, xxxxx xxxxxx účinnosti 1.4.2025.
Xxxxx xxxxxxxxxxxx právních xxxxx jiných xxxxxxxx xxxxxxxx x xxxxxxxx xxxx aktualizováno, xxxxx xx xxxx netýká xxxxxxxxx změna shora xxxxxxxxx právního xxxxxxxx.